Skip to content
Compounder
← Stocks

Atrium Therapeutics Inc

RNA

Held by 1 superinvestor.

Price$14.19
Holders1
Total value$3.5M

SEC 10-K · fundamentals

Business quality

as of 2026-06-30
Revenue growth
-21.9%
Net margin
-672.0%
ROE
-9.4%
FCF margin
-131.9%
What makes a business high quality

SEC 13F · holders

Superinvestors Holding This Security

1 holder · $3.5M combined · this quarter +0 opened / -1 exited

This quarter1 added1 exited
Holders 2 → 1 · last 2q
  • Paul Isaac
    Value$3.5MWeight (prev→now)2.1% → 1.9% ▼
Exited this quarter (1)
Jeremy Grantham

SEC 13F · notes

Written summary

Atrium Therapeutics Inc (RNA) is held by 1 of the superinvestors tracked on Compounder, with a combined $3.5M in reported 13F value. The largest position belongs to Paul Isaac, where it makes up 1.9% of the portfolio.

Over the latest quarter, 0 of the tracked filers opened a new position in RNA, 1 added to existing ones, 0 trimmed, and 1 sold out entirely.

Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-06-30. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.

How to read a 13F

SEC 13F · co-ownership

Also held by these investors

Investors holding Atrium Therapeutics Inc (RNA) also commonly hold →

See which stocks look cheap against a conservative value band. Browse all valued stocks

Also on

Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-13

Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.

Stay Updated

New-quarter 13F moves and valuation updates, to your inbox.